Oppenheimer Starts Biosante (BPA) at Buy
More News related to BPA
- BioSante Pharmaceuticals (BPA) received clarity from and is in agreement with FDA
- Oppenheimer Starts Biosante (BPA) at Buy
- BioSante Pharmaceuticals (BPA) Announces Positive New Findings for Potential Bird Flu Vaccine
- BioSante Pharmaceuticals (BPA) Comments on Women's Health Initiative Coronary Artery Calcium Study published yesterday in NEJM
- Bradley Pharmaceuticals (BDY) Announces Launch of Elestrin
More News related to New Coverage
- BMO Capital Initiates Coverage on Leap Wireless (LEAP) with a Market Perform
- Goldman Sachs Reinstates Citigroup (C) at Neutral
- FBR Research Initiates Coverage on MB Financial (MBFI) with a Market Perform; Taking Advantage of a Fragmented Deposit Market in Chicago
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
Oppenheimer initiates coverageon Biosante Pharmaceuticals (AMEX: BPA) with a Buy rating and $9 price target.
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
